^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EML4-ALK fusion + CDK15-ALK fusion

    i
    Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor, EML4, EMAP Like 4, Restrictedly Overexpressed Proliferation-Associated Protein, Echinoderm Microtubule-Associated Protein-Like 4, Echinoderm Microtubule Associated Protein Like 4, Ropp 120, C2orf2, EMAP-4, EMAPL4, ROPP120, ELP120, CDK15, Cyclin Dependent Kinase 15, Amyotrophic Lateral Sclerosis 2 Chromosomal Region Candidate Gene 7 Protein, Amyotrophic Lateral Sclerosis 2 (Juvenile) Chromosome Region, Candidate 7, Serine/Threonine-Protein Kinase PFTAIRE-2, Serine/Threonine-Protein Kinase ALS2CR7, Cell Division Protein Kinase 15, Cyclin-Dependent Kinase 15, PFTAIRE Protein Kinase 2, PFTAIRE2, ALS2CR7, PFTK2, Serine/Threonine Protein Kinase
    Entrez ID:
    238; 27436; 65061
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over3years
    A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report. (PubMed, Medicine (Baltimore))
    Together, we identified a rare double ALK fusion variant, EML4-ALK and CDK15-ALK, in a patient with lung adenocarcinoma. The patient benefited from crizotinib treatment, which could provide a certain reference for the patients with such gene alteration.
    Clinical • Journal
    |
    ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)
    |
    ALK fusion • EML4-ALK fusion + CDK15-ALK fusion
    |
    cisplatin • Xalkori (crizotinib) • docetaxel